HLA-DR Expression in Neonates After Cardiac Surgery Under Cardiopulmonary Bypass

Nantes University Hospital50 enrolled

Overview

The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in neonates who underwent cardiac surgery with cardiopulmonary bypasss. We hypothesize that HLA-DR expression in neonates is predictive of septic complications after cardiopulmonary bypass

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cardiac Surgery

Interventions

Blood collectionOTHER

A sample of an additional blood tube will be taken in parallel with the blood test carried out for the treatment.

Eligibility

Sex: ALLMax age: 28 Days

Medical Language ↔ Plain English

Inclusion Criteria: * Patients aged ≤ 28 days * Admission after cardiac surgery under cardiopulmonary bypass Exclusion Criteria: * Lack of parental consent

Locations (1)

Nantes University Hospital

Nantes, France

Outcomes

Primary Outcomes

HLA-DR expression

Number of HLA-DR molecules per monocyte (AB/c) determined by flow cytometry on whole blood using a Quantibrite phycoerythrin fluorescence quantitation kit (BD Biosciences) Number of HLA-DR molecules per monocyte (AB/c) determined by flow cytometry on whole blood using a Quantibrite phycoerythrin fluorescence quantitation kit (BD Biosciences)

Time frame: Preoperatively, and 1, 2, 3 and 4 days after the end of cardiopulmonary bypass

Secondary Outcomes

Cytokines measurements

Pro and anti-inflammatory cytokine concentrations in the plasma measured by multiplex immunoassay

Time frame: Preoperatively, and 1, 2, 3 and 4 days after the end of cardiopulmonary bypass

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.